Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Tremelimumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IMFINZI + IMJUDO Improves PFS in Early Liver Cancer
    IMFINZI + IMJUDO Improves PFS in Early Liver Cancer

    02 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260402535842/en/IMFINZI-durvalumab-IMJUDO-tremelimumab-actl-improves-PFS-in-early-liver-cancer

    BUSINESSWIRE
    02 Apr 2026
    Share Share
    AstraZeneca Pharma India to launch Tremelimumab
    AstraZeneca Pharma India to launch Tremelimumab

    23 Sep 2024

    // INDIANPHARMAPOST

    https://www.indianpharmapost.com/news/astrazeneca-pharma-india-to-launch-tremelimumab-16215

    INDIANPHARMAPOST
    23 Sep 2024
    Share Share
    Imfinzi Plus Imjudo Shows 5-Year Survival In Liver Cancer
    Imfinzi Plus Imjudo Shows 5-Year Survival In Liver Cancer

    16 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240916766941/en

    BUSINESSWIRE
    16 Sep 2024
    Share Share
    IMFINZI Reduces Recurrence Risk In Bladder Cancer In NIAGARA Trial
    IMFINZI Reduces Recurrence Risk In Bladder Cancer In NIAGARA Trial

    15 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240915735416/en

    BUSINESSWIRE
    15 Sep 2024
    Share Share
    AstraZeneca's Biologic Imjudon (Tremelimumab) Receives Suppl Approvals in US
    AstraZeneca's Biologic Imjudon (Tremelimumab) Receives Suppl Approvals in US

    24 Jul 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761289

    FDA
    24 Jul 2024
    Share Share
    AstraZeneca's Biologic Imjudo (tremelimumab) Receives Approval in the U.S.
    AstraZeneca's Biologic Imjudo (tremelimumab) Receives Approval in the U.S.

    25 Jan 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761289

    FDA
    25 Jan 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.